RICHMOND HILL, Ontario, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Helix BioPharma Corp. (TSX, FSE: HBP) ("Helix" or the "Company"), an immuno-oncology company developing innovative drug candidates for the ...
In connection with the proposed adoption of the Incentive Program, the Company also announces that it is extending the exercise period of a total of 3,680,000 Warrants (the "Extended Warrants"), all ...
This news release contains forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws. Forward-looking statements ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback